Enhanced antitumor efficacy of integrin-targeted oncolytic adenovirus AxdAdB3-F/RGD on bladder cancer

Urology

Volumn 83, Issue 2, 2014, Pages 508.e13-508.e19

  Wang, Hua ^a   Cai, Zhijian ^b   Yang, Fei ^b   Luo, Juan ^a   Satoh, Makoto ^c   Arai, Yoichi ^d   Li, Dechuan ^a  

^a ZHEJIANG CANCER HOSPITAL   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c Sen en General Hospital   (Japan)

^d TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHAVBETA5 INTEGRIN; ARGINYLGLYCYLASPARTIC ACID; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; E1A PROTEIN; E1B PROTEIN; INTEGRIN; ONCOLYTIC ADENOVIRUS; VITRONECTIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; BLADDER IRRIGATION; BLADDER MUCOSA; CANCER CELL CULTURE; CANCER INHIBITION; CANCER MODEL; CANCER SURVIVAL; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; EMBRYO; FEMALE; FLOW CYTOMETRY; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; MOUSE; MUCOSA CELL; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MODIFICATION; SINGLE DRUG DOSE; SURVIVAL TIME; VIRAL GENE DELIVERY SYSTEM; VIRUS INFECTIVITY;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; FEMALE; GENETIC THERAPY; HUMANS; INTEGRINS; MICE; MICE, INBRED BALB C; OLIGOPEPTIDES; RECEPTORS, VIRUS; URINARY BLADDER NEOPLASMS;

EID: 84895070947     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2013.10.025     Document Type: Article

References (23)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer Statistics, 2012 CA Cancer J Clin 62 2012 10 29
2. M.S. Cookson, H.W. Herr, and Z.F. Zhang et al. The treated natural history of high risk superficial bladder cancer: 15-year outcome J Urol 158 1997 62 67
3. J.J. Meeks, J. Bellmunt, and B.H. Bochner et al. A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer Eur Urol 62 2012 523 533
4. K. Fukuda, M. Abei, and H. Ugai et al. E1A, E1B double-restricted adenovirus for oncolytic gene therapy of gallbladder cancer Cancer Res 63 2003 4434 4440
5. S. Pesonen, I. Diaconu, and V. Cerullo et al. Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors Int J Cancer 130 2012 1937 1947
6. J.M. Burke, D.L. Lamm, and M.V. Meng et al. A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer J Urol 188 2012 2391 2397
7. H. Wang, M. Satoh, and H. Abe et al. Oncolytic viral therapy by bladder instillation using an E1A, E1B double-restricted adenovirus in an orthotopic bladder cancer model Urology 68 2006 674 681
8. J.T. Douglas, M. Kim, and L.A. Sumerel et al. Efficient oncolysis by replicating adenovirus (Ad) in vivo is critically dependent on tumor expression of primary Ad receptors Cancer Res 61 2001 813 817
9. Y. Li, R.C. Pong, and J.M. Bergelson et al. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy Cancer Res 59 1999 325 330
10. M.D. Sachs, K.A. Rauen, and M. Ramamurthy et al. Integrin alpha(v) and coxsackie adenovirus receptor expression in clinical bladder cancer Urology 60 2002 531 536
11. H. Dehari, Y. Ito, and T. Nakamura et al. Enhanced antitumor effect of RGD fiber-modified adenovirus for gene therapy of oral cancer Hum Gene Ther 10 2003 75 85
12. H. Kakizaki, K. Numasawa, and K. Suzuki Establishment of a new cell line derived from a human urinary bladder carcinoma and its characteristics Nihon Hinyokika Gakkai Zasshi 77 1986 1790 1795
13. T. Taya, T. Kobayashi, and K. Tsukahara et al. In vitro culture of malignant tumor tissue from the human urinary tract Jpn J Urol 68 1977 1003 1005
14. T. Shirakawa, R. Sasaki, and T.A. Gardner et al. Drug-resistant human bladder-cancer cells are more sensitive to adenovirus-mediated wild-type p53 gene therapy compared to drug-sensitive cells Int J Cancer 94 2001 282 289
15. Y. Kanegae, G. Lee, and Y. Sato et al. Efficient gene activation in mammalian cells by using recombinant adenovirus expressing site-specific Cre recombinase Nucleic Acids Res 23 1995 3816 3821
16. M. Wakayama, M. Abei, and R. Kawashima et al. E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers Clin Cancer Res 13 2007 3043 3050
17. T. Watanabe, N. Shinohara, and A. Sazawa et al. An improved intravesical model using human bladder cancer cell lines to optimize gene and other therapies Cancer Gene Ther 7 2000 1575 1580
18. M. Taki, S. Kagawa, and M. Nishizaki et al. Enhanced oncolysis by a tropism-modified telomerase-specific replicationselective adenoviral agent OBP-405 ('Telomelysin-RGD') Oncogene 24 2005 3130 3140
19. A. Loskog, T. Hedlund, and K. Wester et al. Human urinary bladder carcinomas express adenovirus attachment and internalization receptors Gene Ther 9 2002 547 553
20. M. Satoh, H. Wang, and S. Ishidoya et al. Oncolytic virotherapy for prostate cancer by E1A, E1B mutant adenovirus Urology 70 2007 1243 1248
21. C. Gomez-Manzano, C. Balague, and R. Alemany et al. A novel E1A-E1B mutant adenovirus induces glioma regression in vivo Oncogene 23 2004 1821 1828
22. L.C. Pagliaro, A. Keyhani, and B. Liu et al. Adenoviral p53 gene transfer in human bladder cancer cell lines: cytotoxicity and synergy with cisplatin Urol Oncol 21 2003 456 462
23. G. Sourvinos, I. Kazanis, and D. Delakas et al. Genetic detection of bladder cancer by microsatellite analysis of p16, RB1 and p53 tumor suppressor genes J Urol 165 2001 249 252